AstraZeneca

Max Healthcare Q1 FY21 Performance

Max Healthcare plays a significant role in combating Covid 19 in Delhi and Mumbai. Treats over 8,000 Covid patients, pioneers…

4 years ago

Wockhardt announces COVID-19 vaccine partnership with UK Government

New Delhi, August 04, 2020: Wockhardt, the global pharmaceutical and biotechnology major today announced that it has entered into an…

4 years ago

Novartis India Limited reconstitutes Board; appoints Sanjay Murdeshwar as Vice Chairman & Managing Director

Mumbai, June 15, 2019: At a meeting held in Mumbai today, the Board of Directors of Novartis India Limited announced…

5 years ago

AstraZeneca opens dedicated Development Operations office in Bengaluru to support expansion of its clinical research footprint in India

The Development Operations Centre supports the development of AstraZeneca’s innovative medicines and hosts clinical trial experts focused on core therapeutic…

5 years ago

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

Shanghai, May 22, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical,…

6 years ago

AstraZeneca India & Business Sweden launch ‘Unnati Healthcare 2.0 – Innovation Challenge’; nominations open till 10th December 2018

Unnati Healthcare 2.0 is a multi-partner initiative with a shared vision of encouraging innovative solutions that can impact the treatment…

6 years ago

Kuwait Pharmaceuticals Market Outlook to 2022: Ken Research

New Delhi, November 24, 2018: The report titled “Kuwait Pharmaceuticals Market Outlook to 2022 – By Type of Drugs (Generic…

6 years ago

AstraZeneca Pharma India gets DCGI nod to market cancer drug in India

New Delhi, August 18, 2018: Drug firm AstraZeneca Pharma India today said it has received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets…

6 years ago

AstraZeneca receives marketing permission for Durvalumab (ImfinziTM) in India

Durvalumabis the only immunotherapy approved for patients with unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Durvalumabwas granted US FDA…

6 years ago

AstraZeneca expands its Global Medicines Development (GMD) Centre in India

GMD India will support AstraZeneca’s global established medicines portfolio; build capabilities in regulatory science, and clinical and patient safety  Bengaluru,…

6 years ago